Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Cut from Oppenheimer

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective dropped by equities research analysts at Oppenheimer from $350.00 to $320.00 in a research note issued to investors on Friday. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer‘s price objective suggests a potential upside of 94.06% from the stock’s current price.

Several other equities analysts have also weighed in on the stock. Citigroup cut their target price on shares of Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating for the company in a report on Wednesday, October 14th. UBS Group reissued a “buy” rating and set a $329.00 price target (down from $550.00) on shares of Alnylam Pharmaceuticals in a report on Friday. Royal Bank Of Canada dropped their price target on shares of Alnylam Pharmaceuticals from $345.00 to $280.00 and set an “outperform” rating on the stock in a research report on Friday. Sanford C. Bernstein cut shares of Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $376.00 to $199.00 in a report on Friday. Finally, Morgan Stanley decreased their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $325.39.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY traded down $9.11 during mid-day trading on Friday, reaching $164.89. The company had a trading volume of 6,058,994 shares, compared to its average volume of 1,507,400. The stock has a market capitalization of $22.06 billion, a P/E ratio of 30.65 and a beta of 0.28. Alnylam Pharmaceuticals has a 52-week low of $163.30 and a 52-week high of $479.79. The stock has a 50 day moving average of $237.78 and a two-hundred day moving average of $287.22. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same period in the previous year, the company posted $2.90 earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 16.7% on a year-over-year basis. On average, analysts expect that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently modified their holdings of ALNY. Legal & General Group Plc purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $278,321,000. Bank of New York Mellon Corp acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at about $148,128,000. Canada Pension Plan Investment Board acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at about $100,618,000. Korea Investment CORP purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $74,553,000. Finally, Wellington Management Group LLP raised its stake in shares of Alnylam Pharmaceuticals by 9.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock valued at $635,296,000 after acquiring an additional 174,482 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported third-quarter revenue of approximately $1.46 billion, up 16.7% year over year and above expectations. Adjusted earnings of $16.26 per share also exceeded consensus by a wide margin, although much of the earnings surprise was attributed to a roughly $1.9 billion tax benefit. Alnylam Q3 earnings and revenue beat
• Positive Sentiment: The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion to $4.5 billion in 2026 TTR-related sales. Alnylam also continued advancing its RNAi pipeline, including the nucresiran program. Alnylam TTR sales outlook
• Neutral Sentiment: Several analysts lowered their price targets following the results, but most still see potential upside. TD Cowen, Goldman Sachs, RBC and Needham retained positive ratings, while Morgan Stanley and Wells Fargo kept equal-weight ratings. Analyst price-target changes
• Negative Sentiment: Investors were concerned about slower U.S. Amvuttra patient starts and decelerating growth in Amvuttra and Onpattro sales. Those trends raised questions about demand and the durability of Alnylam’s core commercial growth. Demand growth concerns
• Negative Sentiment: Management acknowledged that execution needs to improve as uncertainty grows around the TTR franchise. The expansion of the TRITON-CM heart-disease trial to roughly 2,250 patients reinforced concerns about development costs, timing and the path toward a potential launch around 2030. Uncertainty around Alnylam’s TTR franchise
• Negative Sentiment: Analyst sentiment became more cautious: Bernstein downgraded ALNY to market perform, Stifel cut the stock to hold, and multiple firms reduced price targets. A disclosed law-firm investigation related to an earlier stock-price decline adds another potential overhang. Stifel downgrade

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.